natgillin/translations-raw huggingface dataset:
Particularly: blood thinners (oral anticoagulants) or medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except those that you may be given as part of Eptifibatide Accord treatment). 
Naročito: oralne antikoagulanse (lijekove za sprječavanje zgrušavanja krvi) ili lijekove koje sprječavaju nastanak krvnih ugrušaka, uključujući varfarin, dipiridamol, tiklopidin, aspirin (osim onih koje Vam liječnik može dati kao dio liječenja Eptifibatid Accordom).
Similar differences were noted for TIMI major haemorrhage (118 [2.5 %] in early routine use vs. 83 [1.8 %] in delayed provisional use; p=0.016). 
TIMI kriterijima (118 [2,5 %] u ranoj rutinskoj primjeni naspram 83 [1,8 %] pri odgođenoj privremenoj primjeni; p= 0,016).
- Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care units. 
− Eptifibatid Accord se preporučuje za primjenu jedino u odraslih bolesnika, koji se nalaze u bolnici u koronarnim jedinicama.
There was no consistent evidence that eptifibatide increased the risk of major or minor bleeding associated with tissue plasminogen activator in either a PCI or an acute myocardial infarction study. 
Nema konzistentnih dokaza da eptifibatid povećava rizik od većih i manjih krvarenja povezanih s primjenom tkivnog aktivatora plazminogena u studijama s bolesnicima podvrgnutim PCI ili s akutnim infarktom miokarda.
Eptifibatide Accord 2 mg/ml solution for injection contains 57.96 mg (2.52 mmol) of sodium per maximum daily dose. 
Eptifibatid Accord 2 mg/ml otopina za injekciju sadržava 57,96 mg (2,52 mmol) natrija po maksimalnoj dnevnoj dozi.
The recommended dose is 180 microgram/kg administered as a bolus (rapid intravenous injection), followed by an infusion (drip solution) of 2 microgram/kg/minute for up to 72 hours. 
Preporučena doza iznosi 180 mikrograma/kg primijenjena u bolusu (brza intravenska injekcija), nakon koje slijedi infuzija (drip otopina) u dozi od 2 mikrograma/kg/minuti u trajanju do 72 sata.
The experience in humans with overdose of eptifibatide is extremely limited. 
Podaci o predoziranju eptifibatidom u ljudi krajnje su ograničeni.
No statistically significant benefit of early routine eptifibatide strategy was demonstrated in the subgroup of patients who were managed medically or during the medical management periods prior to PCI or CABG. 
Statistički se značajna dobrobit rane rutinske primjene eptifibatida nije pokazala u podskupini bolesnika koji su nekirurški liječeni ili tijekom nekirurškog liječenja prije PCI ili CABG.
The placebo arm was comparable (aspirin 99.7 %, clopidogrel 95.9 %, ticlopidin 2.6 %). 
Placebo krak je bio usporediv (aspirin 99,7 %, klopidogrel 95,9 %, tiklopidin 2,6 %).
In an acute myocardial infarction study involving 181 patients, eptifibatide (in regimens up to a bolus injection of 180 microgram/kg, followed by an infusion up to 2 microgram/kg/min for up to 72 hours) was administered concomitantly with streptokinase (1.5 million units over 60 minutes). 
U ispitivanju akutnog infarkta miokarda koje je uključivalo 181 bolesnika, eptifibatid (pri doziranju bolus injekcija do 180 mikrograma/kg, nakon kojih je uslijedila infuzija u dozama do 2 mikrograma/kg/min tijekom najviše 72 sata) je primijenjen zajedno sa streptokinazom (1,5 milijuna jedinica kroz 60 minuta).
Data are limited on the use of eptifibatide in patients receiving thrombolytic agents. 
Ograničeni su podaci o primjeni eptifibatida u bolesnika koji primaju i trombolitike.
Clinical efficacy and safety 
Klinička djelotvornost i sigurnost Ispitivanje PURSUIT
Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty) (see section 5.1). 
Eptifibatid Accord će najviše koristiti bolesnicima pod visokim rizikom od razvoja infarkta miokarda tijekom prva 3-4 dana nakon nastupa simptoma angine, uključujući, na primjer, one kojima je potrebna rana perkutana transluminalna koronarna angioplastika (PTCA) (vidjeti dio 5.1).
Eptifibatide inhibits platelet aggregation in a dose- and concentration-dependent manner as demonstrated by ex vivo platelet aggregation using adenosine diphosphate (ADP) and other agonists to induce platelet aggregation. 
Eptifibatid inhibira agregaciju trombocita ovisno o dozi i koncentraciji, što je pokazano ex vivo agregacijom trombocita pomoću adenozin-difosfata (ADP) i drugih agonista koji induciraju agregaciju trombocita.
Fatal bleeding (the majority involved central and peripheral nervous system disorders: cerebral or intracranial haemorrhages); pulmonary haemorrhage, acute profound thrombocytopenia, haematoma. 
Vrlo rijetko krvarenje sa smrtnim ishodom (većina se odnosila na poremećaje središnjeg i perifernog živčanog sustava: cerebralno ili intrakranijalno krvarenje); plućna hemoragija, akutna teška trombocitopenija, pojava hematoma
The combination of reduced dose tenecteplase and eptifibatide compared to placebo and eptifibatide significantly increased the risk of both major and minor bleeding when administered concomitantly in an acute ST-elevation myocardial infarction study. 
Kombinacija smanjene doze tenekteplaze i eptifibatida u usporedbi s placebom i eptifibatidom značajno je povisila rizik i velikih i manjih krvarenja kada je primjenjivana istodobno u ispitivanju na bolesnicima s akutnim infarktom miokarda sa ST-elevacijom.
- fatal bleeding. 
− krvarenje sa smrtnim ishodom.
PURSUIT: This was a randomized, double-blind evaluation of the efficacy and safety of eptifibatide versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q-wave myocardial infarction. 
PURSUIT: randomizirana, dvostruka slijepa procjena djelotvornosti i sigurnosti primjene eptifibatida u odnosu na placebo, u smanjenju smrtnosti i (re)infarkta miokarda u bolesnika s nestabilnom anginom ili infarktom miokarda bez Q-zupca.
Frequencies are defined as very common (≥ 1/10); common (≥ 1/100 to< 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to 
Učestalosti su definirane kao: vrlo često (> 1/10), često (> 1/100 i < 1/10), manje često (> 1/1000 i < 1/100), rijetko (> 1/10 000 i <
ESPRIT: This was a double-blind, multicentre, randomized, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo nonemergent percutaneous coronary intervention (PCI) with stent implantation. 
ESPRIT: dvostruko slijepo, multicentrično, randomizirano, placebom kontrolirano ispitivanje paralelnih grupa o sigurnosti i djelotvornosti terapije eptifibatidom u bolesnika predviđenih za nehitnu perkutanu koronarnu intervenciju (PCI) s implantacijom stenta.
Eptifibatide Accord 0.75 mg/ml solution for infusion contains 77.4 mg (3.37 mmol) of sodium per maximum daily dose. 
Eptifibatid Accord 0,75 mg/ml otopina za infuziju sadržava 77,4 mg (3,37 mmol) natrija po maksimalnoj dnevnoj dozi.
If the patient requires emergency or urgent cardiac surgery during the course of eptifibatide therapy, terminate the infusion immediately. 
U slučaju da je tijekom terapije eptifibatidom bolesniku potrebna hitna intervencija ili hitni kardijalni kirurški zahvat, infuziju odmah treba prekinuti.
Table 1: Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population) 
Tablica 1: Incidencija smrti/infarkta miokarda utvrđenog od strane Povjerenstva za kliničke događaje (populacija „liječena prema randomizaciji“)
Concurrent administration of heparin is recommended unless this is contraindicated for reasons such as a history of thrombocytopenia associated with use of heparin (see ‘Heparin administration', section 4.4). 
Preporuča se istodobna primjena heparina ukoliko za to ne postoje kontraindikacije poput anamnestičkog podatka o trombocitopeniji povezanoj s primjenom heparina (vidjeti dio 4.4 'Primjena heparina').
If percutaneous coronary intervention (PCI) is performed during Eptifibatide Accord therapy, the intravenous solution may be continued for up to 96 hours. 
Ako se tijekom liječenja Eptifibatid Accordom provede perkutana koronarna intervencija (PCI), infuzija intravenske otopine može se nastaviti davati i do 96 sati.
All patients received routine standard of care and were randomised to either placebo or eptifibatide (2 bolus doses of 180 microgram/kg and a continuous infusion until discharge from hospital or a maximum of 18-24 hours). 
Svi bolesnici primali su rutinsku standardnu njegu i bili su randomizirani ili u skupinu koja je primala placebo ili u skupinu koja je primala eptifibatid (2 bolus doze od 180 mikrograma/kg i zatim kontinuirana infuzija do otpusta iz bolnice ili maksimalno 18-24 sata).
Eptifibatide Accord infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency CABG surgery or requires an intraortic balloon pump. 
Infuziju Eptifibatid Accorda treba odmah prekinuti ako nastupe okolnosti koje zahtijevaju primjenu trombolitičke terapije ili ako bolesnik mora pristupiti hitnoj ugradnji premosnice koronarne arterije
Adults (≥ 18 years of age) presenting with unstable angina (UA) or non-Q-wave myocardial infarction (NQMI) 
Odrasli (≥ 18 godina starosti) s nestabilnom anginom ili infarktom miokarda bez Q-zupca
Because Eptifibatide Accord inhibits platelet aggregation, caution must be employed when it is used with other medicinal products that affect haemostasis, including ticlopidine, clopidogrel, thrombolytics, oral anticoagulants, dextran solutions, adenosine, sulfinpyrazone, prostacyclin, nonsteroidal anti-inflammatory agents, or dypyridamole (see section 4.5). 
Budući da Eptifibatid Accord inhibira agregaciju trombocita, treba ga pažljivo primjenjivati s drugim lijekovima koji djeluju na hemostazu, uključujući tiklopidin, klopidogrel, trombolitike, oralne antikoagulanse, otopine dekstrana, adenozin, sulfinpirazon, prostaciklin, nesteroidne protuupalne lijekove ili dipiridamol (vidjeti dio 4.5).
Minor bleeding was defined in the PURSUIT trial as spontaneous gross haematuria, spontaneous haematemesis, observed blood loss with a haemoglobin decrease of more than 3 g/dl, or a haemoglobin decrease of more than 4 g/dl in the absence of an observed bleeding site. 
Manje krvarenje definirano je u PURSUIT-u kao spontana teška hematurija, spontana hematemeza, vidljiv gubitak krvi sa smanjenjem hemoglobina za više od 3 g/dl, ili smanjenje hemoglobina za više od 4 g/dl kad mjesto krvarenja nije vidljivo.
In the eptifibatide arm of the trial, virtually all patients received aspirin (99.7 %), and 98.1 % received a thienopyridine, (clopidogrel in 95.4 % and ticlopidine in 2.7 %). 
U kraku ispitivanja koji je primao eptifibatid, gotovo svi bolesnici primali su aspirin (99,7 %), a 98,1 % ih je primalo tienopiridin, (klopidogrel u 95,4 % i tiklopidin u 2,7 %).
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50 % and steady-state plasma levels are approximately doubled. 
U bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina < 50 ml/min), klirens eptifibatida smanjuje se za oko 50 %, a koncentracije u plazmi u stanju dinamičke ravnoteže su približno udvostručene.
In patients undergoing CABG, the incidence of bleeding was not increased by eptifibatide compared to the patients treated with placebo. 
incidencija krvarenja nije bila povišena primjenom eptifibatida u usporedbi s ispitanicima na placebu.
These plasma concentrations are achieved rapidly when the infusion is preceded by a 180microgram/kg bolus. 
Te koncentracije u plazmi se postižu vrlo brzo kada infuziji prethodi bolus injekcija od 180 mikrograma/kg eptifibatida.
While Thrombolysis in Myocardial Infarction TIMI bleeding criteria were used to categorize the incidence of major and minor bleeding in both the PURSUIT and the ESPRIT trials, PURSUIT data was collected within 30 days while ESPRIT data was limited to events within 48 hours or discharge, whichever came first. 
Thrombolysis in Myocardial Infarction) korišteni za kategorizaciju incidencije velikih i manjih krvarenja i u ispitivanju PURSUIT i u ESPRIT, podaci za PURSUIT su prikupljani unutar 30 dana,
- if you have or have had bleeding problems. 
− ako ste imali ili imate problema s krvarenjima.
Administer with caution to patients with hepatic impairment in whom coagulation could be affected (see section 4.3, prothrombin time). 
Lijek treba primjenjivati pažljivo u bolesnika s oštećenjem jetre kod kojih bi to moglo utjecati na koagulaciju (vidjeti dio 4.3,
2 mg/ml : 3.45 mg/ml (0.150 mmol/ml) sodium For the full list of excipients, see section 6.1. 
2 mg/ml : 3,45 mg/ml (0,150 mmol/ml) natrija
How to store Eptifibatide Accord 6. 
Kako čuvati Eptifibatid Accord 6.
The data sources used to determine adverse reaction frequency descriptors included two phase III clinical studies (PURSUIT and ESPRIT). 
Klinička ispitivanja Izvori podataka za procjenu učestalosti nuspojava uključivali su dva klinička ispitivanja faze III
Major bleeding was defined in the PURSUIT trial as either an intracranial haemorrhage or a decrease in haemoglobin concentrations of more than 5 g/dl. 
Velika krvarenja definirana su u PURSUIT ispitivanju ili kao intrakranijalno krvarenje ili kao pad koncentracija hemoglobina za više od 5 g/dl.
The mechanism, whether immune- and/or non-immune-mediated, by which eptifibatide may induce thrombocytopenia is not fully understood. 
Mehanizam kojim eptifibatid može inducirati trombocitopeniju, bez obzira je li ona imunološki i/ili ne-imunološki posredovana, nije u potpunosti razjašnjen.
These may affect up to 1 in 10,000 people 
Mogu se javiti u do 1 na 10000 osoba
Platelet inhibition was readily reversed, with a return of platelet function towards baseline (> 50 % platelet aggregation) 4 hours after stopping a continuous infusion of 2.0 microgram/kg/min. 
Inhibicija trombocita brzo se poništila, pri čemu se > 50 % funkcije trombocita vratila na početne vrijednosti 4 sata nakon prestanka kontinuirane infuzije od 2,0 mikrograma/kg/min.
Eptifibatide Accord should not be used if it is noticed that particulate matter or discoloration is present. 
Eptifibatid Accord se ne smije upotrijebiti ako primijetite čestice ili promjenu boje otopine.
These may affect up to 1 in 100 people 
Mogu se javiti u do 1 na 100 osoba
Eptifibatide did not appear to increase the risk of major and minor bleeding associated with concomitant use of warfarin and dipyridamole. 
Nema pokazatelja da eptifibatid povećava rizik od većih i manjih krvarenja povezanih s istodobnom primjenom varfarina i dipiridamola.
If you develop severe allergic reaction or hives, notify your doctor or hospital pharmacist or nurse immediately. 
Ako nastupi jaka alergijska reakcija ili koprivnjača, odmah o tome obavijestite svog liječnika, bolničkog ljekarnika ili medicinsku sestru.
The undesirable effects are listed by body system and frequency. 
Nuspojave su navedene prema organskim sustavima i učestalosti.
Eptifibatide Accord solution for infusion must be used in conjunction with Eptifibatide Accord solution for injection. 
Eptifibatid Accord otopina za infuziju mora se upotrebljavati zajedno s Eptifibatid Accord otopinom za injekciju.
This study was a 726-center, 27-country, double-blind, randomised, placebo-controlled study in 10,948 patients presenting with UA or NQMI. 
randomizirana, placebom kontrolirana studija, u koju je uključeno 10 948 bolesnika sa simptomima NA ili NQIM.
The pharmacokinetics of eptifibatide are linear and dose proportional for bolus doses ranging from 90 to 250 microgram/kg and infusion rates from 0.5 to 3.0 microgram/kg/min. 
Farmakokinetika eptifibatida je linearna i proporcionalna dozi bolusa od 90 do 250 mikrograma/kg i brzini infuzije od 0,5 do 3,0 mikrogram/kg/min.
Protection of Eptifibatide Accord solution from light is not necessary during administration. 
Zaštita otopine Eptifibatid Accorda od svjetlosti nije potrebna tijekom primjene.
In patients with moderate renal impairment, (creatinine clearance 30 - 50 ml/min) 100 % inhibition was achieved at 24 hours following administration of 2 microgram/kg/min. 
U bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30 - 50 ml/min) postignuta je 100 % -tna inhibicija 24 sata nakon primjene 2 mikrograma/kg/min.
Very common Bleeding (major and minor bleeding including femoral artery access, CABGrelated, gastrointestinal, genitourinary, retroperitoneal, intracranial, haematemesis, haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other). 
Vrlo često krvarenje (velika i manja krvarenja uključujući i krvarenje na mjestu pristupa femoralnoj arteriji, vezana uz CABG, gastrointestinalno, urogenitalno, retroperitonealno, intrakranijalno krvarenje, hematemeza, hematurija, oralno/orofaringealno krvarenje, pad hemoglobina/hematokrita i drugo)
The primary endpoint event rate was 11.9 % in patients who received a reduced dose (1microgram/kg/min) vs 11.2 % in patients who received the standard dose (2 microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.81). 
Stopa događaja primarnog ishoda je iznosila 11,9 % u bolesnika koji su primili smanjenu dozu (1 mikrogram/kg/min) naspram 11,2 % u bolesnika koji su primili standardnu dozu (2 mikrograma/kg/min), kada je eptifibatid primijenjen kao rana rutinska terapija (p=0,81).
If you notice any signs of bleeding, notify your doctor or hospital pharmacist or nurse immediately. 
Ako primijetite bilo kakav znak krvarenja, odmah obavijestite svog liječnika ili bolničkog ljekarnika ili medicinsku sestru.
Eptifibatide Accord solution for injection must be used in conjunction with Eptifibatide Accord solution for infusion. 
Eptifibatid Accord otopina za injekciju mora se upotrebljavati zajedno s Eptifibatid Accord otopinom za infuziju.
With delayed provisional eptifibatide administration, the event rates were 10 % vs 11.5 % in patients who received reduced dose and standard dose respectively (p=0.61). 
Uz odgođenu privremenu primjenu eptifibatida, stope događaja su za bolesnike sa smanjenom dozom lijeka iznosile 10 % u odnosu na 11,5 % u bolesnika na standardnoj dozi (p=0,61).
Citric acid monohydrate Sodium hydroxide Water for injections 
Citratna kiselina hidrat Natrijev hidroksid Voda za injekcije
Eptifibatide Accord 2 mg/ml: Each ml of solution for injection contains 2 mg of eptifibatide. 
Eptifibatid Accord 2mg/ml: jedan ml otopine za injekciju sadrži 2 mg eptifibatida.
The other ingredients are citric acid monohydrate, sodium hydroxide and water for injections. 
Drugi sastojci su citratna kiselina hidrat, natrijev hidroksid i voda za injekcije.
Eptifibatide Accord 2 mg/ml: The clear, colourless solution is contained in a 10 ml glass vial, which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal. 
Eptifibatid Accord 2 mg/ml: bistra bezbojna otopina u staklenoj bočici od 10 ml, zatvorenoj s gumenim čepom (butil guma) i aluminijskim „flip-off“ zaštitnim poklopcem.
All potential bleeding sites, (e.g., catheter insertion sites; arterial, venous, or needle puncture sites; cutdown sites; gastrointestinal and genitourinary tracts) must be observed carefully. 
Potrebno je pažljivo nadzirati sva mjesta mogućeg krvarenja, kao što su npr. mjesto uvođenja katetera, mjesto uboda igle u venu ili arteriju, rezove, gastrointestinalni i urogenitalni sustav.
− severe reduction in the number of platelets (blood cells necessary for blood clotting). 
− ozbiljno smanjenje broja trombocita (krvnih stanica neophodnih za zgrušavanje krvi).
Eptifibatide Accord 0.75 mg/ml: Each ml of solution for infusion contains 0.75 mg of eptifibatide. 
Eptifibatid Accord 0,75 mg/ml: jedan ml otopine za infuziju sadržava 0,75 mg eptifibatida.
Eptifibatide Accord 0.75 mg/ml: The clear, colourless solution is contained in a 100 ml glass vial, which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal. 
Eptifibatid Accord 0,75 mg/ml: bistra bezbojna otopina u staklenoj bočici od 100 ml, zatvorenoj s gumenim čepom (butil guma) i aluminijskim „flip-off“ zaštitnim poklopcem.
MI could also be reported following CEC adjudication of an investigator report. 
Infarkt miokarda se mogao prijaviti i nakon što je Povjerenstvo za kliničke događaje provjerilo ispitivačevo izvješće.
Common side effects These may affect up to 1 in 10 people - inflammation of a vein. 
Mogu se javiti u do 1 na 10 osoba − upala vene.
For a 2.0 microgram/kg/min infusion, mean steady-state plasma eptifibatide concentrations range from 1.5 to 2.2 microgram/ml in patients with coronary artery disease. 
Kod infuzije od 2,0 mikrogram/kg/min u stanju dinamičke ravnoteže eptifibatida u plazmi iznose od 1,5 do 2,2 mikrogram/kg u bolesnika s koronarnom bolesti srca.
In patients with severe renal impairment (creatinine clearance < 30 ml/min) administered 1microgram/kg/min , 80 % inhibition was achieved in more than 80 % of patients at 24 hours. 
U bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min) u kojih je primijenjen lijek u dozi od 1 mikrogram/kg/min, nakon 24 sata postignuta je 80 % -tna inhibicija u više od 80 % bolesnika.
0.75 mg/ml : 1.72 mg/ml (0.075 mmol/ml) sodium For the full list of excipients, see section 6.1. 
0,75 mg/ml : 1,72 mg/ml (0,075 mmol/ml) natrija
Eptifibatide Accord 0.75 mg/ml solution for infusion: 100 ml vial, pack of one vial. 
Eptifibatid Accord 0,75 mg/ml otopina za infuziju: bočica sa 100 ml, kutija s jednom bočicom.
- if you have or have had severe kidney or liver problems. 
− ako ste imali ili imate ozbiljnih problema s bubrezima ili jetrom
The primary endpoint analysis [quadruple composite of death, MI, urgent target vessel revascularisation (UTVR) and thrombolytic bail-out (TBO) at 48 hours] showed a 37 % relative and 3.9 % absolute reduction in the eptifibatide group (6.6 % events versus 10.5 %, p= 0.0015). 
Analiza primarne mjere ishoda[kompozitna mjera sastavljena od četiri komponente: smrti, infarkta miokarda, hitne revaskularizacije ciljne krvne žile i tzv. 'bail-out' trombolize tijekom 48 sati] pokazala je 37 % relativno, te 3,9 % apsolutno smanjenje u skupini koja je primala eptifibatid (6,6 % događaja vs 10,5 %, p = 0,0015).
Excipients: Citric acid monohydrate, sodium hydroxide, water for injections. 
Pomoćne tvari: citratna kiselina hidrat, natrijev hidroksid, voda za injekcije.
The rate of infusion was 2.0 microgram/kg/min for patients with serum creatinine ≤ 175 micromols/l or 1.0 microgram/kg/min for serum creatinine > 175 up to 350 micromols/l. 
Bolesnici s razinom serumskog kreatinina ≤ 175 mikromola/l primili su infuziju od 2,0 mikrograma/kg/min, a bolesnici s razinom serumskog kreatinina > 175 do 350 mikromola/l infuziju od 1,0 mikrograma/kg/min.
At the highest infusion rates (1.3 microgram/kg/min and 2.0 microgram/kg/min) studied, eptifibatide was associated with an increased incidence of bleeding and transfusions compared to the incidence seen when streptokinase was given alone. 
2,0 mikrograma/kg/min), eptifibatid je bio povezan s povećanim rizikom krvarenja i transfuzije u usporedbi s incidencijom prilikom primjene same streptokinaze.
- if you have recently had bleeding from your stomach, intestines, bladder or other organs, for example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding) 
− ako ste nedavno imali krvarenje iz želuca, crijeva, mokraćnog mjehura ili drugih organa, na primjer ako ste uočili abnormalnu pojavu krvi u stolici ili mokraći (osim menstrualnog krvarenja) u proteklih 30 dana − ako ste u proteklih 30 dana doživjeli moždani udar ili bilo koju drugu vrstu izljeva krvi u mozak